News
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
After Achillion Pharmaceuticals (NASDAQ: ACHN) priced its shares that Johnson & Johnson (NYSE: JNJ) is selling at $2.75 each, the company is rallying back 19.5% as of 3:15 p.m. EST.Johnson....
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health (NASDAQ: GHDX) recorded a $1.1 million profit during the third quarter, something it's been shooting for as it's improved its bottom line for each of the last nine consecutive....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Predicting the future isn't hard at all. Predicting the future accurately is a different matter altogether.I wanted to state that at the outset before attempting to predict how things will unfold....
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Last week on the Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Shares of Sangamo Therapeutics (NASDAQ: SGMO) rose over 16% today after the company announced that the first patient had been dosed in a phase 1/2 trial evaluating the potential for its....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....
Here's Why Acorda Therapeutics Got Crushed Today
Shares of biopharma Acorda Therapeutics (NASDAQ: ACOR) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. The company is increasing the....
Why Achillion Pharmaceuticals Stock Is Falling Today
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are falling hard today after the company announced that Johnson & Johnson (NYSE: JNJ) has decided to sell 18.4 million of the drugmaker's....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's next top pick for running the Department of Health and Human Services (HHS) is Eli Lilly & Co. (NYSE: LLY) executive Alex Azar, and that's drawing the ire of patient advocates....
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported....
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
Bayer AG (NASDAQOTH: BAYRY) has entered into a collaborative partnership with Loxo Oncology (NASDAQ: LOXO) that could make it a global leader in cancer drugs that are used in patients based on....
Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today
After pricing an equity offering that will dilute current investors but help shore up its balance sheet, shares in Synergy Pharmaceuticals (NASDAQ: SGYP) are tumbling 15.6% as of 1:45 p.m.....
Keryx Biopharma Down 17% Despite Drug Approval
Last week, Keryx Biopharmaceuticals (NASDAQ: KERX) fell a whopping 17% after missing analyst estimates for its key drug, Auryxia, which is used to control phosphorus levels in patients with....
BASTIDE : Bonne dynamique au 1er trimestre 2017-2018 Chiffre d'affaires : + 22%
En K€ - 1er trimestre
2016-2017
2017-2018
Variation
Chiffre d'affaires
50 738
61 765
+ 21,7%
Le Groupe Bastide réalise un début d'exercice très solide avec un....
5 Supernova Stocks That Have Flown Under the Radar
Recently on the Rule Breakers Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....